Baseline demographics and disease characteristics
| Characteristic . | Patients (N = 12) . |
|---|---|
| Age at time of consent, y | |
| Median (range) | 52.5 (22-75) |
| >60 | 5 (42) |
| Level of disease at time of consent, median (range), % | |
| MFC | 0.054 (0-1.1) |
| PCR only | 0.05 (0.01-0.09) |
| Method used for MRD detection at enrollment | |
| MFC only | 8 (67) |
| PCR only | 2 (17) |
| MFC and PCR | 2 (17) |
| B lineage | 10 (83) |
| Ph+ | 6 (50) |
| P190 | 4 (67) |
| P210 | 2 (33) |
| Ph− | 6 (50) |
| Normal cytogenetics | 5 (83) |
| Complex cytogenetics | 1 (17) |
| No. of prior therapies | |
| Median (range) | 1.5 (1-7) |
| 1 | 6 (50) |
| ≥2 | 6 (50) |
| No. with prior HCT | 3 (25) |
| No. with prior CAR T cells | 3 (25) |
| Characteristic . | Patients (N = 12) . |
|---|---|
| Age at time of consent, y | |
| Median (range) | 52.5 (22-75) |
| >60 | 5 (42) |
| Level of disease at time of consent, median (range), % | |
| MFC | 0.054 (0-1.1) |
| PCR only | 0.05 (0.01-0.09) |
| Method used for MRD detection at enrollment | |
| MFC only | 8 (67) |
| PCR only | 2 (17) |
| MFC and PCR | 2 (17) |
| B lineage | 10 (83) |
| Ph+ | 6 (50) |
| P190 | 4 (67) |
| P210 | 2 (33) |
| Ph− | 6 (50) |
| Normal cytogenetics | 5 (83) |
| Complex cytogenetics | 1 (17) |
| No. of prior therapies | |
| Median (range) | 1.5 (1-7) |
| 1 | 6 (50) |
| ≥2 | 6 (50) |
| No. with prior HCT | 3 (25) |
| No. with prior CAR T cells | 3 (25) |
Values are reported as n (%) of patients unless otherwise indicated.